According to the Press Release at the Wall Street Journal, all patient data will remain anonymous and these are the research phases which will be available:
- - Phase 2, 3 or 4 studies used as part of a regulatory approval submitted to the U.S. Food and Drug Administration (FDA) on or after 1999;
- - Phase 2, 3 or 4 global studies with a first patient visit after January
- 1, 2007; and
- - Phase 2, 3 or 4 global or regional/local studies in indications approved in both the U.S. and EU with a first patient visit after January 1, 2014.